$60.10
0.180.3%
最終更新: Oct 14, 9:37 AM
$59.50
-0.42-0.7%
Benzinga
Benzinga
Benzinga
水曜日, 10 14
Benzinga
© 2026 Benzinga | All Rights Reserved
PTC Therapeutics (PTCT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
PTC Therapeutics (PTCT) は、7 30, 2026日にfiscal yearの2026に関するガイダンスを直近で発表しました。同社は当期の売上高を$1.18B - $1.28Bの範囲と予想しています。
以前のガイダンスと比較して、PTC Therapeuticsは売上高予測を以前の範囲である引き上げから$1.08B - $1.18Bに引き上げました。
PTC Therapeuticsは、23から10 27, 2022の間に7 30, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 8 times and lowered it 6 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.31 | $-0.41 | $-0.33 | $-1.14 |
| Actual | $0.92 | $-0.03 | $-1.67 | $0.20 |
| Surprise | +196.8% | +92.7% | -406.1% | +117.5% |
| Revenue | ||||
| Estimate | $292.7M | $227.5M | $295.4M | $175.5M |
| Actual | $360.5M | $272.6M | $164.7M | $211.0M |
| Surprise | +23.2% | +19.8% | -44.3% | +20.2% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.27 | $0.15 | $0.07 | $0.16 |
| Revenue | ||||
| Consensus | $304.4M | $321.5M | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $0.92 | $0.31 | 196.8 % |
| Q1 | May 7, 2026 | $-0.03 | $-0.41 | 92.7 % |
| Q4 | Feb 19, 2026 | $-1.67 | $-0.33 | -406.1 % |
| Q3 | Nov 4, 2025 | $0.20 | $-1.14 | 117.5 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $360.52M | $292.70M | 23.2 % |
| Q1 | May 7, 2026 | $272.55M | $227.52M | 19.8 % |
| Q4 | Feb 19, 2026 | $164.68M | $295.44M | -44.3 % |
| Q3 | Nov 4, 2025 | $211.01M | $175.55M | 20.2 % |